Transparently report on the process of moving from evidence to recommendation

We welcome the expert consensus recommendation from the European Hematology Association (EHA) by Jannik Stemler and colleagues1 on antifungal prophylaxis in adult patients with acute myeloid leukaemia given novel targeted therapies. The authors examined 18 novel targeted agents that are approved and licensed for the treatment of patients with acute myeloid leukaemia, and they formed evidence-based recommendations or consensus-based statements for various targeted agents. However, we noticed that the process of the guidance from evidence to recommendation is not transparent and can be improved.